RxDoctor Payments Data

Akwasi Achampong, DO

Internal Medicine · Elmont, NYNPI 1427168210

Payments from drug & device makers

$793in general payments, 2019–2025

Across 36 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$125
  • Novartis$85
  • Lilly USA, LLC$79
  • Novo Nordisk$74
  • Johnson & Johnson$74
  • Merck$71
  • plus $285 from 7 others

What the payments were for

  • Food & beverage$793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$793 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$36,395
Medicare patients
68
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate73$75,116
OzempicSemaglutide41$43,015
EliquisApixaban29$24,467
MounjaroTirzepatide23$23,337
JanumetSitagliptin Phos/Metformin Hcl21$20,859
EntrestoSacubitril/Valsartan14$17,731
XareltoRivaroxaban13$16,660
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,679
Lidocaine18$2,173
Atorvastatin Calcium185$1,555
Metoprolol Succinate94$1,295
Amlodipine Besylate235$1,271
Albuterol Sulfate HfaAlbuterol Sulfate42$1,263
Nifedipine ErNifedipine31$1,249
Metformin Hcl152$989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$71$95,97594 claims
Novo NordiskOzempic$74$43,01541 claims
PfizerEliquis$34$24,46729 claims
Lilly USA, LLCMounjaro$79$23,33723 claims
NovartisEntresto$85$17,73114 claims
Johnson & JohnsonXarelto$74$16,66013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elmont

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →